Iatrogenic lesions of the skeleton
https://doi.org/10.14341/osteo12249
Abstract
Osteoporotic fractures are an important public health problem due to their negative impact on the quality of life and life expectancy, as well as high cost of treatment and rehabilitation. Along with the major risk factors for osteoporotic fractures, such as low bone mineral density (BMD), age, low body weight, frequent falls and previous fractures, an important secondary risk factor, especially among susceptible individuals, is taking certain medications. The difficulty in assessing fracture risk when taking various drugs, as well as the development of appropriate methods of prevention and treatment, is often due to the absence of large randomized trials with a sufficient level of evidence, as well as the heterogeneity of the main risk factors for fractures in studied groups of patients. We focus on the main groups of drugs for which there is evidence of a negative impact on bone metabolism, BMD and fracture risk. In addition to drugs, bone metabolism is also influenced by bariatric surgery, transplantation of solid organs, gonadectomy for various diseases.
This article is the RePrint from the original publication in Obesity and Metabolism 2016; 13(2); pp. 41-47. doi: 10.14341/omet2016241-47
About the Authors
Galina A. Melnichenko
Endocrinology Research Centre; I.M. Sechenov’s First Moscow State Medical University
Russian Federation
Competing Interests:
Russian Federation
MD, PhD, Professor
Competing Interests:
No conflict of interest
Elizaveta O. Mamedova
Endocrinology Research Centre
Russian Federation
Competing Interests:
Russian Federation
MD, PhD
Competing Interests:
No conflict of interest
References
1. O'Sullivan S, Grey A. Adverse skeletal effects of drugs – beyond Glucocorticoids. Clin Endocrinol (Oxf). 2015;82(1):12-22. doi: 10.1111/cen.12549.
2. Compston J. Skeletal effects of drugs. In: Rosen C.J. editor. Primer on the Metabolic Bone Diseases and Disorders of Mineral metabolism. 8th ed. Wiley-Blackwell; 2013. P. 520–526. doi:10.1002/9781118453926.ch64.
3. Лесняк О.М., Баранова И.А., Торопцова Н.В. Клинические рекомендации «Диагностика, профилактика и лечение глюкокортикоидного остеопороза у мужчин и женщин 18 лет и старше». – Ярославль. ИПК «Литера». – 2013. – 48 с. [Lesnyak OM, Baranova IA, Toroptsova NV. Klinicheskie rekomendatsii «Diagnostika, profilaktika i lechenie glyukokortikoidnogo osteoporoza u muzhchin i zhenshchin 18 let i starshe». – Yaroslavl': IPK «Litera»; 2013 (In Russ).]
4. Дедов И.И., Мазурина Н.В., Огнева Н.А., и др. Нарушения метаболизма витамина D при ожирении. // Ожирение и метаболизм. – 2011. – № 2. – С. 3-10. [Dedov II, Mazurina NV, Ogneva NA, et al. Narusheniya metabolizma vitamina D pri ozhirenii. Obesity and metabolism. 2011;(2):3-10 (In Russ)] doi:10.14341/2071-8713-4946
5. Shahinian VB, Kuo Y-F, Freeman JL, Goodwin JS. Risk of Fracture after Androgen Deprivation for Prostate Cancer. N Engl J Med. 2005;352(2):154-164. doi: 10.1056/NEJMoa041943.
6. Eastell R, Adams JE, Coleman RE, et al. Effect of Anastrozole on Bone Mineral Density: 5-Year Results From the Anastrozole, Tamoxifen, Alone or in Combination Trial 18233230. J Clin Oncol. 2008;26(7):1051-1057. doi: 10.1200/jco.2007.11.0726.
7. Kim MK, Yun K-J, Kim M-H, et al. The effects of thyrotropin-suppressing therapy on bone metabolism in patients with well-differentiated thyroid carcinoma. Bone. 2015;71:101-105. doi: 10.1016/j.bone.2014.10.009.
8. Wang LY, Smith AW, Palmer FL, et al. Thyrotropin Suppression Increases the Risk of Osteoporosis Without Decreasing Recurrence in ATA Low- and Intermediate-Risk Patients with Differentiated Thyroid Carcinoma. Thyroid. 2015;25(3):300-307. doi: 10.1089/thy.2014.0287.
9. Ljunggren Ö, Bolinder J, Johansson L, et al. Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin. Diabetes Obes Metab. 2012;14(11):990-999. doi: 10.1111/j.1463-1326.2012.01630.x.
10. Meier C, Schwartz AV, Egger A, Lecka-Czernik B. Effects of diabetes drugs on the skeleton. Bone. 2016;82:93-100. doi: 10.1016/j.bone.2015.04.026.
11. Partti K, Heliövaara M, Impivaara O, et al. Skeletal Status in Psychotic Disorders: A Population-Based Study. Psychosom Med. 2010;72(9):933-940. doi: 10.1097/PSY.0b013e3181f7abd3.
12. Shen C, Chen F, Zhang Y, et al. Association between use of antiepileptic drugs and fracture risk: A systematic review and meta-analysis. Bone. 2014;64:246-253. doi: 10.1016/j.bone.2014.04.018.
13. Rejnmark L, Vestergaard P, Heickendorff L, et al. Loop Diuretics Increase Bone Turnover and Decrease BMD in Osteopenic Postmenopausal Women: Results From a Randomized Controlled Study With Bumetanide. J Bone Miner Res. 2005;21(1):163-170. doi: 10.1359/jbmr.051003.
14. Lim LS, Fink HA, Blackwell T, et al. Loop Diuretic Use and Rates of Hip Bone Loss and Risk of Falls and Fractures in Older Women. J Am Geriatr Soc. 2009;57(5):855-862. doi: 10.1111/j.1532-5415.2009.02195.x.
15. Lim LS. Loop Diuretic Use and Increased Rates of Hip Bone Loss in Older MenThe Osteoporotic Fractures in Men Study. Arch Intern Med. 2008;168(7):735. doi: 10.1001/archinte.168.7.735.
Supplementary files
Review
For citations:
Melnichenko G.A., Mamedova E.O. Iatrogenic lesions of the skeleton. Osteoporosis and Bone Diseases. 2017;20(4):19-25. (In Russ.) https://doi.org/10.14341/osteo12249
Views:
1412
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
